title: A new approach to a Lyme disease vaccine.
abstract: A single recombinant outer surface protein A (OspA) antigen designed to contain protective elements from 2 different OspA serotypes (1 and 2) is able to induce antibody responses that protect mice against infection with either Borrelia burgdorferi sensu stricto (OspA serotype-1) or Borrelia afzelii (OspA serotype-2). Protection against infection with B burgdorferi ss strain ZS7 was demonstrated in a needle-challenge model. Protection against B. afzelii species was shown in a tick-challenge model using feral ticks. In both models, as little as .03 μg of antigen, when administered in a 2-dose immunization schedule with aluminum hydroxide as adjuvant, was sufficient to provide complete protection against the species targeted. This proof of principle study proves that knowledge of protective epitopes can be used for the rational design of effective, genetically modified vaccines requiring fewer OspA antigens and suggests that this approach may facilitate the development of an OspA vaccine for global use.
authors.affiliation: Baxter Innovations GmbH, Biomedical Research Center, Orth an der Donau, Austria. ian.livey@baxter.com
authors.forename: Ian
authors.initials: I
authors.lastname: Livey
authors.forename: Maria
authors.initials: M
authors.lastname: O'Rourke
authors.forename: Andreas
authors.initials: A
authors.lastname: Traweger
authors.forename: Helga
authors.initials: H
authors.lastname: Savidis-Dacho
authors.forename: Brian A
authors.initials: BA
authors.lastname: Crowe
authors.forename: P Noel
authors.initials: PN
authors.lastname: Barrett
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Yang
authors.forename: John J
authors.initials: JJ
authors.lastname: Dunn
authors.forename: Benjamin J
authors.initials: BJ
authors.lastname: Luft
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D025065:Borrelia burgdorferi / Q000276:immunology*; D015748:Borrelia burgdorferi Group / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D008074:Lipoproteins / Q000276:immunology*; D008193:Lyme Disease / Q000276:immunology* / Q000517:prevention & control*; D022123:Lyme Disease Vaccines / Q000276:immunology*; D051379:Mice; D008809:Mice, Inbred C3H; D023421:Models, Animal; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D013987:Ticks / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D000939:Epitopes; D008074:Lipoproteins; D022123:Lyme Disease Vaccines; C072045:OspA protein; D011994:Recombinant Proteins